RET and thyroid gland carcinoma: Furthermore, we observed the RET variant (rs1800861, COSM4418405) in 98% of patients, reaching 100% prevalence in advanced-stage of HCC, mirroring its known associations with adamantinomatous craniopharyngioma (Jastania et al., 2020), thyroid cancer (Minna et al., 2022) and chronic myeloid leukemia (Sklarz et al., 2018).